Related Experiment Videos
Bipolar affective disorder and medication therapy: identifying barriers
Adriana Inocenti Miasso1, Silvia Helena De Bortoli Cassiani, Luiz Jorge Pedrão
1University of Sao Paulo at Ribeirao Preto College of Nursing, WHO Collaborating Center for Nursing Research Development, Brazil. amiasso@eerp.usp.br
Revista Latino-Americana De Enfermagem
|October 4, 2008
Summary
People with bipolar affective disorder (BAD) face significant barriers to continuous medication adherence. They experience affective and cognitive losses, alongside life limitations, leading to ambivalence about treatment.
Area of Science:
- Psychiatry and Behavioral Sciences
- Qualitative Health Research
- Sociology of Health
Background:
- Bipolar affective disorder (BAD) requires continuous medication management for symptom control.
- Understanding patient-perceived barriers is crucial for improving treatment adherence.
- Existing research often overlooks the lived experiences of individuals with BAD regarding medication.
Purpose of the Study:
- To identify and explore the barriers encountered by individuals with bipolar affective disorder (BAD) concerning continuous medication adherence.
- To gain insight into the subjective experiences of patients and their relatives regarding treatment challenges.
Main Methods:
- Qualitative study employing a Grounded Theory approach, guided by Symbolic Interactionism.
- Data collected through in-depth interviews and observations.
- Participants included 14 individuals diagnosed with BAD and 14 of their relatives.
Main Results:
- Two primary categories of barriers emerged: perceived affective and cognitive losses, and significant life limitations.
- Individuals with BAD reported ambivalence towards medication adherence due to anticipated prejudice and functional impairments.
- Participants felt that any treatment path involved unavoidable negative consequences in daily life.
Conclusions:
- Continuous medication adherence in bipolar affective disorder (BAD) is hindered by profound personal and social barriers.
- The perception of inevitable losses and limitations contributes to patient ambivalence and challenges treatment engagement.
- Future interventions should address these psychosocial barriers to improve long-term medication adherence and quality of life for individuals with BAD.
Related Concept Videos
01:30Bipolar Disorder
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
01:28Psychosis and Antipsychotic Drugs: Overview
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...